Clinical Trial Update: C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration [Phase 4]

View source ↗

Summary

Phase 4 trial update for C-Trelin oral disintegrating tablet 5 mg in ataxia due to spinocerebellar degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ataxia
• Spinocerebellar Degeneration

Drugs mentioned

• C-Trelin (unknown)

Snippet

Sponsor: HLB Pharmaceutical Co., Ltd. | Conditions: Spinocerebellar Degeneration | Phase 4 | Status: COMPLETED